TEVA (Teva Pharmaceutical Industries) Asset Impairment Charge : $1,953 Mil (TTM As of Mar. 2025)

View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries Asset Impairment Charge?

Teva Pharmaceutical Industries's Asset Impairment Charge for the three months ended in Mar. 2025 was $77 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was $1,953 Mil.

Teva Pharmaceutical Industries Asset Impairment Charge Historical Data

The historical data trend for Teva Pharmaceutical Industries's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Asset Impairment Charge Chart

Teva Pharmaceutical Industries Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

6,546.00

584.00

2,447.00

1,078.00

2,555.00

Teva Pharmaceutical Industries Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Asset Impairment Charge	Get a 7-Day Free Trial															679.00	530.00	549.00	797.00	77.00

Teva Pharmaceutical Industries Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,953 Mil.

Teva Pharmaceutical Industries Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

TEVJF:USA TEVA N:Mexico TEVA:Israel 0LER:UK TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEV:Bulgaria TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Executives

Richard D Francis	officer: President and CEO	IM LANGACHER 44, GREIFENSEE V8 8606
Eric A Hughes	officer: See "Remarks"	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell	officer: Exec. VP, European Commercial	5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Eliyahu Sharon Kalif	officer: EVP, Chief Financial Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Mark Sabag	officer: EVP, Global Human Resources	5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Roberto Mignone	director	C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Angus Grant	officer: EVP, Business Development	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss	officer: Chief Accounting Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway	officer: See "Remarks"	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape	officer: Executive VP Global Operations	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Dov Bergwerk	officer: Acting Chief Legal Officer	C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Sven Dethlefs	officer: EVP Global Marketing&Portfolio	5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark	officer: Exec. VP Chief Legal Officer	5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Hafrun Fridriksdottir	officer: Executive VP, Global R&D	400 INTERPACE PARKWAY, PARSIPPANY NJ 07054